Latest Content

New psychiatry drugs target dementia agitation, ADHD, depression, TRD, and schizophrenia—see which novel mechanisms may reach the FDA next.

FDA clears MIND1 trial testing NRX-101 plus robotic TMS to curb suicidality in treatment-resistant depression, with military-focused sites.

HHS targets psychiatric overprescribing; expert Joseph F. Goldberg, MD, urges careful deprescribing—stop ineffective medications and replace with evidence-based treatments.

Explore how neuromelanin-sensitive MRI noninvasively tracks long-term dopamine and noradrenaline system changes.

Learn how dual antipsychotics can mask the true cause of high prolactin, and how stepwise switches to aripiprazole or clozapine restore cycles.

New cohort and global data link teen high-potency cannabis use to higher psychosis, bipolar, and suicide risks. Here's what psychiatrists and mental health clinicians should know in the era of legalization.

HHS rolls out a plan to curb psychiatric overprescribing, pushing deprescribing guidance as APA and AFSP urge caution and access to care.

New analysis ranks lumateperone top for adjunctive MDD symptom relief, with minimal weight gain vs other atypical antipsychotics.

Low soluble α2δ‑1 disrupts brain excitation‑inhibition balance in schizophrenia.

Learn when CBT/IPT beats medications, when to combine antidepressants, and why patient preference drives depression recovery in 6–12 weeks in this podcast.

New data shows stable symptoms when switching from atypical antipsychotics to Cobenfy using cross-titration.

In the wake of the FDA fast-track of psychedelic therapies, we want to hear your clinical pearls for our May theme.

A psychiatrist and psychiatric nurse practitioner discuss collaboration and patient support.